May 22, 2018
Source: Press Release, Prague
SOTIO, a biotechnology company owned by the PPF Group, today announces the presentation of new promising clinical data from its ovarian and lung cancer clinical trials evaluating DCVAC, an active cellular immunotherapy product. Data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States.
“Data from our Phase II clinical trials evaluating DCVAC medicinal products show significant benefit of using these products in combination with standard chemotherapy in patients with ovarian and lung cancer. The results are both statistically and clinically significant. Compared to patients who did not receive DCVAC, the risk of progression or death decreased significantly,” commented Radek Spíšek, Chief Executive Officer of SOTIO. “We are very happy that results of our clinical trials have been accepted for presentation at ASCO,” he added.
Data from the SOV01 clinical trial assessing the DCVAC/OvCa medicinal product in patients with ovarian cancer will be orally presented at Clinical Science Symposium in the session “Engaging the Immune System in Ovarian Cancer”:
Presentation title: “Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.”
Abstract 5509 available online, Location: S406; Time: June 3, 2018 at 9:45 a.m. – 11:15 a.m.
The abstract from the SLU01 clinical trial with the DCVAC/LuCa medicinal product targeting patients with non-small cell lung cancer was chosen for poster presentation in Poster Session “Lung Cancer—Non-Small Cell Metastatic”:
Title: Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC: primary analysis of a phase 2, open-label, randomized, multicenter trial.
Abstract 9051 available online, Poster Board: #374, Location: Hall A; Time: June 3, 2018 at 8.00 a.m. – 11.30 a.m.
More details, presentations and posters will be disclosed during their presentation at ASCO 2018.
The SOTIO DCVAC product candidates are active cellular immunotherapy treatments which are produced individually for each patient using the patient’s own dendritic cells (which form part of the immune system) to induce an immune reaction against tumor antigens. SOTIO is developing three product candidates using the DCVAC platform to affect multiple different cancers in various stages of the disease - DCVAC/OvCa for patients with ovarian cancer, DCVAC/PCa for patients with prostate cancer and DCVAC/LuCa for patients with lung cancer.
The company is currently testing the safety and efficacy of investigational medicinal treatment DCVAC through multiple Phase I to Phase III clinical trials.